10 April 2025
: Case report 
Navigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study
Challenging differential diagnosis, Unusual setting of medical care, Rare disease
Daniel Wang Qiu
1BCEF, Yi-Jin Lin Lee 1BCEF, Garima Tripathi123BCEF, Dito Anurogo 4BCEF, Cheng-Fu Ni5CD, Wei-Chin Chang 6BCD, Hao-Sheng Fu3BCD, J. Timothy Qiu137ABCDEFG*
DOI: 10.12659/AJCR.946585
Am J Case Rep 2025; 26:e946585
Table 1. Trials for immunotherapies used in mesothelioma.
| Study name | Year | Immunotherapy drugs | Results summary |
|---|---|---|---|
| PROMISE-meso []10 | 2020 | Pembrolizumab | ORR: 22% vs 6%, Median PFS: 2.5 vs 3.4 months |
| KEYNOTE-158 []11 | 2021 | Pembrolizumab | Median PFS: 6.2 months, Median OS: 12.2 months |
| CONFIRM []12 | 2021 | Nivolumab | Median PFS: 3 months vs 1.8 months (placebo), OS: 10.2 vs 6.9 months |
| CheckMate 743 []13 | 2021 | Nivolumab, ipilimumab | 3-year outcomes, first-line treatment |
| NIBIT-MESO-1 []14 | 2021 | Tremelimumab, durvalumab | Median PFS (second-line): 8 months, Median OS: 16.6 months |
| MAPS-2 []15 | 2021 | Nivolumab, ipilimumab | Disease control rate(DCR): 40–52%, Median OS: 15.9 months |
| BEAT-meso []16 | 2024 | Bevacizumab, atezolizumab | PFS was 9.2 months (Atezolizumab + Bevacizumab + Chemotherapy) vs 7.6 months (Bevacizumab + Chemotherapy); OS was 20.5 vs 18.1 months, ORR: 55% vs 49% |
| DREAM3R []17 | 2022 | Durvalumab with chemotherapy | Ongoing phase 3 trial, results awaited |
| IND227 []18 | 2023 | Pembrolizumab + platinum + pemetrexed (CP) | CP + pembrolizumab showed improved overall survival (19.8 months vs 8.9 months) and response rate (47% vs 19%) compared to CP alone |